Thomas H. Kean, Jr. (R-NJ) bought $1,001 - $15,000 of Abbott Laboratories (ABT) on January 29, 2026, according to a transaction report disclosed February 19, 2026. USAspending records an action by the Department of Health and Human Services on March 19, 2026, 49 days after the nearest trade, on a definitive contract (75A50122C00046) with Abbott Laboratories whose total value is $65.5M. Kean sits on the House Committee on Energy and Commerce, which oversees the Department of Health and Human Services. March 19, 2026 was the latest action USAspending listed for that contract when it was pulled on June 19, 2026; the contract itself may be years older, and $65.5M is its total value, not the amount of that action. The records do not show who placed the trade or that anyone involved knew of the contract.
A lead built from public records, not a finding of wrongdoing. Each record below is checked against its source every day; a lead that stops matching is withdrawn.
Thomas H. Kean, Jr. sits on the House Committee on Energy and Commerce, which oversees the Department of Health and Human Services.
Linked by ticker ABT to Abbott Laboratories (ABT); USAspending recipient Abbott Laboratories (parent: Abbott Laboratories) carries the company's name. Contracts whose recipient the name check could not tie to the company are left out.
Department of Health and Human Services contract 75A50122C00046 with Abbott Laboratories: total value $65.5M, latest recorded action March 19, 2026 (49 days after the nearest trade). USAspending description: "ABBOTT: TO CONDUCT CLINICAL TRAINING AND VALIDATION STUDIES TO SUPPORT A FUTURE FDA MARKETING APPLICATION WITH AN EXPANDED INDICATION FOR USE OF THE ABBOTT TBI TEST ? TO AID IN THE DIAGNOSIS OF TRAUMATIC BRAIN INJURY IN ADULTS AND PEDIATRIC".
Source recordSTOCK Act transaction report disclosed for ABT, Feb 19, 2026.
| Type | Record |
|---|---|
| trade | Bought ABT for $1,001 - $15,000 on January 29, 2026; disclosed February 19, 2026.Source |
| contract | Department of Health and Human Services contract 75A50122C00046 with Abbott Laboratories: total value $65.5M, latest recorded action March 19, 2026 (49 days after the nearest trade). USAspending description: "ABBOTT: TO CONDUCT CLINICAL TRAINING AND VALIDATION STUDIES TO SUPPORT A FUTURE FDA MARKETING APPLICATION WITH AN EXPANDED INDICATION FOR USE OF THE ABBOTT TBI TEST ? TO AID IN THE DIAGNOSIS OF TRAUMATIC BRAIN INJURY IN ADULTS AND PEDIATRIC".Source |
| committee | Thomas H. Kean, Jr. sits on the House Committee on Energy and Commerce, which oversees the Department of Health and Human Services. |
| company match | Linked by ticker ABT to Abbott Laboratories (ABT); USAspending recipient Abbott Laboratories (parent: Abbott Laboratories) carries the company's name. Contracts whose recipient the name check could not tie to the company are left out. |